Mesalamine is under clinical development by Dr. Falk Pharma and currently in Phase II for Eosinophilic Esophagitis. According to GlobalData, Phase II drugs for Eosinophilic Esophagitis have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mesalamine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mesalamine overview
Mesalazine (Salofalk, Canasa, Salo, Osperzo) is an aminosalicylate anti-inflammatory agent. It is formulated as suppositories, suspension, aerosol foam, enema for rectal route of administration, tablets, film coated tablets and granules for oral route of administration. It is indicated for the treatment of ulcerative colitis, eosinophilic esophagitis and ulcerative proctitis and crohn’s disease. It was under development for the treatment of diverticulitis, collagenous colitis and pediatric ulcerative colitis.
Dr. Falk Pharma overview
Dr. Falk Pharma develops and distributes innovative medicines for gastroenterology and hepatology therapeutic areas. The company offers products for various diseases such as autoimmune hepatitis, Crohn’s disease, eosinophilic esophagitis, chronic constipation, colorectal cancer screening, hemorrhoidal disease, irritable bowel syndrome, microscopic colitis, primary biliary cholangitis and ulcerative colitis. It commercializes its products under the brand names Azafalk, Ursofalk, Budenofalk, Endofalk, Jorveza, Mucofalk and Salofalk, among others. The company operates through its subsidiaries in Austria, the Netherlands, Spain, Portugal, France, the UK and Italy. Dr. Falk Pharma is headquartered in Freiburg, Baden-Wurttemberg, Germany.
For a complete picture of Mesalamine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
